The purpose of this study is to assess the
effectiveness, safety, and tolerability of GLS-1200 to prevent SARS-CoV-2 infection
in healthcare personnel. GLS-1200 contains quinine diluted in saline
(salt water). Pre-clinical studies have shown that quinine stimulates nasal
cells to secrete compounds that may prevent growth of bacteria and reduce
viruses from reproducing.
Treatment: Participants will be randomized to either quinine or placebo group (saline or salt water) at a 2:1 ratio.
Duration of the Study: Participants will self-administer study drug three times daily (TID) for 4 weeks. A follow-up visit will be made at 6 weeks to assess participant health since some cases of SARS-CoV-2 infection may not be apparent until after the treatment period has ended.